Literature DB >> 23294633

Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice.

Christoph Köhler1, Maja Dinekov, Jürgen Götz.   

Abstract

We studied underlying pathomechanisms in tauopathies using pR5 mice that express the P301L tau mutation found in familial forms of frontotemporal dementia. In a longitudinal study we investigated the functional status of glycogen synthase kinase-3 and correlated it with the appearance of distinct tau phospho-epitopes. Neurons displaying increases in activating phosphorylation of glycogen synthase kinase-3α/β at tyrosine 279/216 also showed an intense rather than moderate AT8 (phospho-Ser202/Thr205 tau) immunoreactivity, and immunoreactivity for AT100 (phospho-Ser212/Thr214 tau) and phosphorylated Ser422, phospho-epitopes associated with fibrillar tau pathology. These neurons were rare in 8.5-month-old, but numerous in 18.5- and 28-month-old pR5 mice. Two antibodies that detect phosphotyrosine residues more generally only stained these neurons. In contrast, we did not find increased phosphotyrosine in neuronal perikarya of mice with an amyloid-β plaque pathology. Our results suggest a link between increased tyrosine phosphorylation and tau aggregation. They also reveal for the mouse models studied, that tau- rather than an amyloid-β peptide-induced pathology is associated with increased neuronal tyrosine phosphorylation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23294633     DOI: 10.1016/j.neurobiolaging.2012.11.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  13 in total

1.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia.

Authors:  Sally Kelliny; Jing Xiong; Larisa Bobrovskaya; Xin-Fu Zhou
Journal:  Neurotox Res       Date:  2021-10-02       Impact factor: 3.911

Review 3.  Protein phosphorylation in neurodegeneration: friend or foe?

Authors:  Sandra Tenreiro; Katrin Eckermann; Tiago F Outeiro
Journal:  Front Mol Neurosci       Date:  2014-05-13       Impact factor: 5.639

4.  Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn.

Authors:  Di Xia; Jürgen Götz
Journal:  Front Mol Neurosci       Date:  2014-05-13       Impact factor: 5.639

5.  Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.

Authors:  Rebecca M Nisbet; Ann Van der Jeugd; Gerhard Leinenga; Harrison T Evans; Phillip W Janowicz; Jürgen Götz
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

6.  Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Upregulation of AMPK Ameliorates Alzheimer's Disease-Like Tau Pathology and Memory Impairment.

Authors:  Lin Wang; Na Li; Fang-Xiao Shi; Wei-Qi Xu; Yun Cao; Ying Lei; Jian-Zhi Wang; Qing Tian; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2020-06-09       Impact factor: 5.682

Review 8.  Tau protein modifications and interactions: their role in function and dysfunction.

Authors:  Anna Mietelska-Porowska; Urszula Wasik; Marcelina Goras; Anna Filipek; Grazyna Niewiadomska
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

9.  PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.

Authors:  Helois Radford; Julie A Moreno; Nicholas Verity; Mark Halliday; Giovanna R Mallucci
Journal:  Acta Neuropathol       Date:  2015-10-08       Impact factor: 17.088

10.  Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.

Authors:  P Dourlen; F J Fernandez-Gomez; C Dupont; B Grenier-Boley; C Bellenguez; H Obriot; R Caillierez; Y Sottejeau; J Chapuis; A Bretteville; F Abdelfettah; C Delay; N Malmanche; H Soininen; M Hiltunen; M-C Galas; P Amouyel; N Sergeant; L Buée; J-C Lambert; B Dermaut
Journal:  Mol Psychiatry       Date:  2016-04-26       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.